Stanniocalcin-1 is a Modifier of Oxygen-Induced Retinopathy Severity

References

• Faia LJTM. Retinopathy of prematurity. In: Ryan SJSS, Hinton DR, Schachat AP, editors. Retinopathy of prematurity. Retina: Saunders, an imprint of Elsevier Inc. 2013:1920–32.
   Google Scholar
• Lepore D, Quinn GE, Molle F, Baldascino A, Orazi L, Sammartino M, Purcaro V, Giannantonio C, Papacci P, Romagnoli C. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology. 2014;121(11):2212–19. doi:10.1016/j.ophtha.2014.05.015.
   PubMed Web of Science ®Google Scholar
• Fu Z, Nian S, Li SY, Wong D, Chung SK, Lo AC. Deficiency of aldose reductase attenuates inner retinal neuronal changes in a mouse model of retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2015; Epub ahead of print. doi:10.1007/s00417-015-3024-0.
   Web of Science ®Google Scholar
• Hartnett ME. Pathophysiology and mechanisms of severe retinopathy of prematurity. Ophthalmology. 2015;122(1):200–10. doi:10.1016/j.ophtha.2014.07.050.
   PubMed Web of Science ®Google Scholar
• Group CfRoPC. Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results. Pediatrics. 1988;81(5):697–706.
   PubMedGoogle Scholar
• Good WV ETfRoPCG. Final results of the early treatment for retinopathy of prematurity (etrop) randomized trial. Trans Am Ophthalmol Soc 2004;102:233–48.
   PubMedGoogle Scholar
• Chung EJ, Kim JH, Ahn HS, Koh HJ. Combination of laser photocoagulation and intravitreal bevacizumab (avastin) for aggressive zone i retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2007;245:1727–30. doi:10.1007/s00417-007-0661-y.
   PubMed Web of Science ®Google Scholar
• Travassos A, Teixeira S, Ferreira P, Regadas I, Travassos AS, Esperancinha FE, Prieto I, Pires G, Van VR, Valido A, et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging. 2007;38:233–37.
   PubMedGoogle Scholar
• Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML, Salazar-Teran N, Chan RV. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina. 2008;28:S19–S25. doi:10.1097/IAE.0b013e318159ec6b.
   PubMed Web of Science ®Google Scholar
• Menke MN, Framme C, Nelle M, Berger MR, Sturm V, Wolf S. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone ii, stage 3 with plus disease. BMC Ophthalmol. 2015;15:20. doi:10.1186/s12886-015-0001-7.
   PubMed Web of Science ®Google Scholar
• Bührer C, Bassler D. Oral propranolol: a new treatment for infants with retinopathy of prematurity? Neonatology. 2015;108(1):49–52. doi:10.1159/000381659.
   PubMed Web of Science ®Google Scholar
• Fierson WM. Ophthalmology AAOPSo, American Academy of O, American Association for Pediatric O, Strabismus, American Association of Certified O. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2018;142(6):189–95.
   PubMed Web of Science ®Google Scholar
• Kong L, Bhatt AR, Demny AB, Coats DK, Li A, Rahman EZ, O’Brian ES, Steinkuller PG. Pharmacokinetics of bevacizumab and its effects on serum vegf and igf-1 in infants with retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2015;56(2):956–61. doi:10.1167/iovs.14-15842.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Jiang Y, Bai Y, Wen J, Chen L. Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab. Graefes Arch Clin Exp Ophthalmol. 2016;254(1):31–36.
   Google Scholar
• Wang H, Zhang SX, Hartnett ME. Signaling pathways triggered by oxidative stress mediate features of severe retinopathy of prematurity. JAMA Ophthalmol. 2013;131(1):80–85. doi:10.1001/jamaophthalmol.2013.986.
   PubMed Web of Science ®Google Scholar
• Rathi S, Jalali S, Patnaik S, Shahulhameed S, Musada GR, Balakrishnan D, Rani PK, Kekunnaya R, Chhablani PP, Swain S, et al. Abnormal complement activation and inflammation in the pathogenesis of retinopathy of prematurity. Front Immunol. 2017;8:1868. doi:10.3389/fimmu.2017.01868.
   PubMed Web of Science ®Google Scholar
• Rivera JC, Holm M, Austeng D, Morken TS, Zhou TE, Beaudry-Richard A, Sierra EM, Dammann O, Chemtob S. Retinopathy of prematurity: inflammation, choroidal degeneration, and novel promising therapeutic strategies. J Neuroinflammation. 2017;14(1):165. doi:10.1186/s12974-017-0943-1.
   PubMed Web of Science ®Google Scholar
• Ito Y, Zemans R, Correll K, Yang IV, Ahmad A, Gao B, Mason RJ. Stanniocalcin-1 is induced by hypoxia inducible factor in rat alveolar epithelial cells. Biochemical and Biophysical Research Communications. 2014;452(4):1091–97. doi:10.1016/j.bbrc.2014.09.060.
   PubMed Web of Science ®Google Scholar
• Shi X, Wang J, Qin Y. Recombinant adeno-associated virus-delivered hypoxia-inducible stanniocalcin-1 expression effectively inhibits hypoxia-induced cell apoptosis in cardiomyocytes. J Cardiovasc Pharmacol. 2014;64(6):522–29. doi:10.1097/FJC.0000000000000146.
   PubMed Web of Science ®Google Scholar
• Durukan Tolvanen A, Westberg JA, Serlachius M, Chang AC, Reddel RR, Andersson LC, Tatlisumak T. Stanniocalcin 1 is important for poststroke functionality, but dispensable for ischemic tolerance. Neuroscience. 2013;229:49–54. doi:10.1016/j.neuroscience.2012.10.062.
   PubMed Web of Science ®Google Scholar
• Zhang K, Lindsberg PJ, Tatlisumak T, Kaste M, Olsen HS, Andersson LC. Stanniocalcin: a molecular guard of neurons during cerebral ischemia. Proc Natl Acad Sci U S A. 2000;97(7):3637–42. doi:10.1073/pnas.070045897.
   PubMed Web of Science ®Google Scholar
• Roddy GW, Rosa RH Jr., Oh JY, Ylostalo JH, Bartosh TJ Jr., Choi H, Lee RH, Yasumura D, Ahern K, Nielsen G, et al. Stanniocalcin-1 rescued photoreceptor degeneration in two rat models of inherited retinal degeneration. Mol Ther. 2012;20(4):788–97. doi:10.1038/mt.2011.308.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Ko JH, Yun JH, Kim JA, Kim TE, Lee HJ, Kim SH, Park KH, Oh JY. Stanniocalcin-1 protects retinal ganglion cells by inhibiting apoptosis and oxidative damage. PLoS One. 2013;8(5):e63749. doi:10.1371/journal.pone.0063749.
   PubMed Web of Science ®Google Scholar
• Roddy GW, Viker KB, Winkler NS, Bahler CK, Holman BH, Sheikh-Hamad D, Roy Chowdhury U, Stamer WD, Fautsch MP. Stanniocalcin-1 is an ocular hypotensive agent and a downstream effector molecule that is necessary for the intraocular pressure-lowering effects of latanoprost. Invest Ophthalmol Vis Sci. 2017;58(5):2715–24. doi:10.1167/iovs.16-21004.
   PubMed Web of Science ®Google Scholar
• Huang L, Garcia G, Lou Y, Zhou Q, Truong LD, DiMattia G, Lan XR, Lan HY, Wang Y, Sheikh-Hamad D. Anti-inflammatory and renal protective actions of stanniocalcin-1 in a model of anti-glomerular basement membrane glomerulonephritis. Am J Pathol. 2009;174(4):1368–78. doi:10.2353/ajpath.2009.080476.
   PubMed Web of Science ®Google Scholar
• Penn JS, Henry MM, Tolman BL. Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat. Pediatr Res. 1994;36(6):724–31. doi:10.1203/00006450-199412000-00007.
   PubMed Web of Science ®Google Scholar
• Wang H, Yang Z, Jiang Y, Hartnett ME. Endothelial nadph oxidase 4 mediates vascular endothelial growth factor receptor 2-induced intravitreal neovascularization in a rat model of retinopathy of prematurity. Mol Vis. 2014;20:231–41.
   PubMed Web of Science ®Google Scholar
• Chang AC, Cha J, Koentgen F, Reddel RR. The murine stanniocalcin 1 gene is not essential for growth and development. Mol Cell Biol. 2005;25(23):10604–10. doi:10.1128/MCB.25.23.10604-10610.2005.
   PubMed Web of Science ®Google Scholar
• Stahl A, Chen J, Sapieha P, Seaward MR, Krah NM, Dennison RJ, Favazza T, Bucher F, Lofqvist C, Ong H, et al. Postnatal weight gain modifies severity and functional outcome of oxygen-induced proliferative retinopathy. Am J Pathol. 2010;177(6):2715–23. doi:10.2353/ajpath.2010.100526.
   PubMed Web of Science ®Google Scholar
• Ohkouchi S, Block GJ, Katsha AM, Kanehira M, Ebina M, Kikuchi T, Saijo Y, Nukiwa T, Prockop DJ. Mesenchymal stromal cells protect cancer cells from ros-induced apoptosis and enhance the warburg effect by secreting stc1. Mol Ther. 2012;20(2):417–23. doi:10.1038/mt.2011.259.
   PubMed Web of Science ®Google Scholar
• Moreno-Miralles I, Ren R, Moser M, Hartnett ME, Patterson C. Bone morphogenetic protein endothelial cell precursor-derived regulator regulates retinal angiogenesis in vivo in a mouse model of oxygen-induced retinopathy. Arterioscler Thromb Vasc Biol. 2011;31(10):2216–22. doi:10.1161/ATVBAHA.111.230235.
   PubMed Web of Science ®Google Scholar
• Connor KM, Krah NM, Dennison RJ, Aderman CM, Chen J, Guerin KI, Sapieha P, Stahl A, Willett KL, Smith LE. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc. 2009;4(11):1565–73. doi:10.1038/nprot.2009.187.
   PubMed Web of Science ®Google Scholar
• Marmorstein AD, Johnson AA, Bachman LA, Andrews-Pfannkoch C, Knudsen T, Gilles BJ, Hill M, Gandhi JK, Marmorstein LY, Pulido JS. Mutant best1 expression and impaired phagocytosis in an ipsc model of autosomal recessive bestrophinopathy. Sci Rep. 2018;8(1):4487. doi:10.1038/s41598-018-21651-z.
   PubMed Web of Science ®Google Scholar
• Sato T, Kusaka S, Hashida N, Saishin Y, Fujikado T, Tano Y. Comprehensive gene-expression profile in murine oxygen-induced retinopathy. Br J Ophthalmol. 2009;93(1):96–103. doi:10.1136/bjo.2008.142646.
   PubMed Web of Science ®Google Scholar
• Tang SE, Wu CP, Wu SY, Peng CK, Perng WC, Kang BH, Chu SJ, Huang KL. Stanniocalcin-1 ameliorates lipopolysaccharide-induced pulmonary oxidative stress, inflammation, and apoptosis in mice. Free Radic Biol Med. 2014;71:321–31. doi:10.1016/j.freeradbiomed.2014.03.034.
   PubMed Web of Science ®Google Scholar
• Nguyen A, Chang AC, Reddel RR. Stanniocalcin-1 acts in a negative feedback loop in the prosurvival erk1/2 signaling pathway during oxidative stress. Oncogene. 2009;28(18):1982–92. doi:10.1038/onc.2009.65.
   PubMed Web of Science ®Google Scholar
• Pan JS, Huang L, Belousova T, Lu L, Yang Y, Reddel R, Chang A, Ju H, DiMattia G, Tong Q, et al. Stanniocalcin-1 inhibits renal ischemia/reperfusion injury via an amp-activated protein kinase-dependent pathway. J Am Soc Nephrol. 2015;26(2):364–78. doi:10.1681/ASN.2013070703.
   PubMed Web of Science ®Google Scholar
• Law AY, Ching LY, Lai KP, Wong CK. Identification and characterization of the hypoxia-responsive element in human stanniocalcin-1 gene. Mol Cell Endocrinol. 2010;314(1):118–27. doi:10.1016/j.mce.2009.07.007.
   PubMed Web of Science ®Google Scholar
• Zhao M, Xie W, Tsai SH, Hein TW, Rocke BA, Kuo L, Rosa RH Jr. Intravitreal stanniocalcin-1 enhances new blood vessel growth in a rat model of laser-induced choroidal neovascularization. Invest Ophthalmol Vis Sci. 2018;59(2):1125–33. doi:10.1167/iovs.17-23083.
   PubMed Web of Science ®Google Scholar
• Law AY, Wong CK. Stanniocalcin-1 and −2 promote angiogenic sprouting in huvecs via vegf/vegfr2 and angiopoietin signaling pathways. Mol Cell Endocrinol. 2013;374(1–2):73–81. doi:10.1016/j.mce.2013.04.024.
   PubMed Web of Science ®Google Scholar
• He LF, Wang TT, Gao QY, Zhao GF, Huang YH, Yu LK, Hou YY. Stanniocalcin-1 promotes tumor angiogenesis through up-regulation of vegf in gastric cancer cells. J Biomed Sci. 2011;18:39. doi:10.1186/1423-0127-18-39.
   PubMed Web of Science ®Google Scholar
• Keir LS, Firth R, Aponik L, Feitelberg D, Sakimoto S, Aguilar E, Welsh GI, Richards A, Usui Y, Satchell SC, et al. Vegf regulates local inhibitory complement proteins in the eye and kidney. J Clin Invest. 2017;127(1):199–214. doi:10.1172/JCI86418.
   PubMed Web of Science ®Google Scholar